S-1
Gastric Neoplasm
Merck Sharp & Dohme LLCPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Gastric Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | BB |
arx788 Ambrx, Inc. | Phase 1 | CC |
Ompenaclid Inspirna, Inc. | Phase 1 | CC |
Same molecule, other indications
S-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →